Get the Weekly Intelligence Brief — top committee picks every Sunday.

CVSA vs SFD

Covista Inc. vs Smithfield Foods, Inc. — AI-powered side-by-side comparison
CVSA
Covista Inc.
60
Watch
VS
SFD
Smithfield Foods, Inc.
61
Buy
MetricCVSASFD
AI Score 60 61
Price $128.45 $22.73
P/E Ratio 16.60× 8.84×
ROE 17.4% 14.5%
Revenue Growth YoY
Gross Margin 57.3% 13.4%
Debt / Equity 0.63× 0.37×
Dividend Yield 0.0% 4.7%
RSI (14) 48.4 23.1
Beta 0.623 -0.5027
Expected Upside +6.0% +6.5%

AI Committee View

Current Innellis committee reasoning for CVSA versus SFD.
SFD leads by 1 points.

SFD scores 61/100 (Buy) versus CVSA at 60/100 (Watch).

CVSA Committee View
67% agreement
6 analysts

The primary driver is roe of 16.6% shows genuine earnings power backing the valuation. The main limiting factor is current ratio of 0.82 is tight -- limited short-term liquidity cushion. The committee is constructive but not yet at full conviction.

Bull Case
  • ROE of 16.6% shows genuine earnings power backing the valuation — Value
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
  • Current ratio of 0.82 is tight -- limited short-term liquidity cushion — Risk
  • Bollinger bandwidth of 24.6% signals elevated volatility — Risk
SFD Committee View
50% agreement
6 analysts

The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.29) -- balance sheet can absorb a shock. Technical Analyst remains cautious — rsi at 23 is in oversold territory (could mean either capitulation or a bounce setup). This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • P/E of 9.5 is inexpensive for the broad market — Value
  • Price-to-book of 1.3x is a discount to asset value — Value
  • ROE of 15.2% shows genuine earnings power backing the valuation — Value
Bear Case
  • Revenue declining -13.1% YoY -- this is not a growth story right now — Growth
  • EPS declining -16.9% YoY despite any revenue growth — Growth
  • RSI at 23 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
CVSA Full Analysis SFD Full Analysis